Israel's Teva completes Auspex deal, has new arguments on Mylan offer

Teva Pharmaceutical Industries ($TEVA) said it has completed its $3.2 billion acquisition of Auspex Pharmaceuticals, a U.S.-based biopharmaceutical company specializing in development of nervous system therapies.

The Israel-based drugmaker said Auspex would strengthen its own pipeline of innovative drugs for the nervous system and in turn it would apply its commercialization skills to the Auspex drugs.

Auspex has focused on underserved diseases such as Huntington's, tardive dyskinesia and Tourette's. Its Huntington's molecule-development platform, SD-809, recently completed a Phase III clinical trial and won orphan-drug status from the U.S. FDA.

In a separate release, Teva presented a new set of arguments in support of its attempted takeover of Mylan ($MYL), saying a merger "makes compelling strategic, financial and cultural sense."

- here's the Auspex release
- and the Teva/Mylan release